Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System

July 12, 2022 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is furthering progress in discussions with investors and developing the financing model towards the next step of the development process with its Nanoemulsion drug delivery system. The Company is confident that it will progress towards this next step.The early feasibility study was intended to serve as a demonstration...

Read more

Tissium Appoints Maria Sainz as Independent Board Member

July 12, 2022 3:00 AM

PARIS, FRANCE and BOSTON, MA / ACCESSWIRE / July 12, 2022 / TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has appointed Maria Sainz as an independent member of the Board of Directors.Ms. Sainz has over 30 years of experience in the medical technology industry. In the last 10 years, she held the position of President and CEO of three medical devices companies...

Read more

Health Canada Approves the Application To Initiate Construction of Cube Psytech's Facility

July 11, 2022 9:00 AM

VANCOUVER, BC / ACCESSWIRE / July 11, 2022 / Cube Psytech Inc. (the "Company" or " CUBE"), a biopharmaceutical and biotechnology company focused on the research and development of functional and psychedelic mushroom technologies for use in natural healthcare products, is pleased to announce the approval of the Company's application to Health Canada to begin Phase 1 construction on its Ramara, Ontario property in conjunction with the issuance of...

Read more

Edesa Biotech to Present at ARDS Drug Development Summit

July 11, 2022 8:30 AM

TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the 2nd Annual ARDS Drug Development Summit being held July 13-15, 2022 in Boston, Mass.Dr. Nijhawan's presentation is scheduled for 8:25 am ET on July 14, 2022. Among his remarks, he is expected...

Read more

enVVeno Medical Announces the Issuance of a New Unique Category III CPT Code Covering the Insertion of a Bioprosthetic Valve into the Femoral Vein

July 8, 2022 8:05 AM

New Current Procedural Terminology (CPT®) III code establishes a reimbursement pathway for the VenoValveThe VenoValve is a potential first-in-class treatment for patients suffering from Chronic Venous Insufficiency (CVI) of the deep veins of the legThere are currently no effective treatments for patients with deep venous CVIThe VenoValve is currently being evaluated in leading hospitals throughout the U.S. in the ongoing SAVVE U.S. pivotal...

Read more

Hemogenyx Pharmaceuticals PLC Announces Investor Webinar Recording

July 8, 2022 7:45 AM

LONDON, ENGLAND / ACCESSWIRE / July 8, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that following the live investor webinar presented by Dr Vladislav Sandler, Chief Executive Officer and Co-Founder of Hemogenyx Pharmaceuticals held on 6 July 2022, a recording of the webinar is now available to view on the Company's YouTube channel at https://youtu.be/LFH95Zw8e6YEnquiries:Hemogenyx Pharmaceuticals...

Read more

Cannadips is Expanding Internationally, Leveraging Lexaria's DehydraTECH

July 7, 2022 9:05 AM

KELOWNA, BC / ACCESSWIRE / July 7, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its DehydraTECH licensee Boldt Runners Corporation, owners of the Cannadips Brand, has expanded manufacturing agreements to include Europe, Japan, and South Africa."We are extremely grateful for our longstanding relationship with Lexaria and look...

Read more

Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study

July 7, 2022 9:00 AM

DNase-based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indicationsSystemic DNase program initially targeting multi-billion-dollar indications including pancreatic carcinomaFRAMINGHAM, MA / ACCESSWIRE / July 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies...

Read more

Sharon O'Keefe Joins Apollo Endosurgery Board of Directors

July 6, 2022 7:00 AM

Seasoned healthcare leader brings 30 years of hospital system and medical technology expertiseAUSTIN, TX / ACCESSWIRE / July 6, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced that Sharon O'Keefe has joined the company's Board of Directors, effective July 6, 2022."We are thrilled to welcome Sharon to the Apollo Endosurgery...

Read more

First in Human Subjects Enrolled in Aqualung Therapeutics Phase 1A Study Evaluating Safety, Tolerability and Pharmacokinetics of ALT-100

July 5, 2022 9:10 PM

TUCSON, AZ / ACCESSWIRE / July 5, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced today that their first two patients have been enrolled in the phase 1A healthy human volunteer Study. The data from this study will be used to understand and validate dosing and safety of the humanized monoclonal antibody...

Read more

Hemogenyx Pharmaceuticals PLC Announces Change of Registered Office

July 1, 2022 7:45 AM

LONDON, ENGLAND / ACCESSWIRE / July 1, 2022 / Hemogenyx Pharmaceuticals plc announces that its registered office address has changed with immediate effect to 6th Floor,60 Gracechurch Street, London, EC3V 0HR,United Kingdom.Enquiries:Hemogenyx Pharmaceuticals plchttps://hemogenyx.comDr Vladislav Sandler, Chief Executive Officer & [email protected] Redmond, [email protected] SP Angel Corporate Finance...

Read more

BrainChip's 'This is our Mission' Podcast Deep Dives on Essential AI

June 30, 2022 2:30 PM

LAGUNA HILLS, CA / ACCESSWIRE / June 30, 2022 / BrainChip Holdings Ltd (ASX:BRN) (OTCQX:BRCHF) (ADR:BCHPY), the world's first commercial producer of neuromorphic AI IP, today announced that Chief Marketing Officer, Jerome Nadel is the featured guest on the latest "This is our Mission" podcast. Nadel joins Vice President of Worldwide Sales, Rob Telson to discuss the opportunities for BrainChip's neuromorphic technology to become the de facto...

Read more

Biovica's CFO Will Leave in December 2022

June 30, 2022 12:05 PM

UPPSALA, SE / ACCESSWIRE / June 30, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II):Biovica, active in cancer diagnostics, today announces that the company's CFO and deputy CEO Cecilia Driving today has submitted her letter of resignation. A process to recruit a replacement is immediately initiated. Cecilia Driving, who has been Biovica's CFO since 2016, will continue in her current role until December 31, 2022."During her...

Read more

Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting

June 30, 2022 11:00 AM

LONDON, ENGLAND / ACCESSWIRE / June 30, 2022 / Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.Proxy Voting ResultsOrdinary ResolutionsVotes for% of votes cast forVotes Against% of votes cast againstTotal votes castTotal votes...

Read more

Biovica International AB – Annual Report for the Financial Year 2021/2022 Published

June 30, 2022 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / June 30, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)Annual report for the financial year 2021/2022 for Biovica International AB is published today on our website.Financials - BiovicaContactAnders Rylander, CEOPhone: +46-18-444 48 35E-mail: [email protected] Driving, EVP CFOPhone +46-73-125 92 47E-mail: [email protected] - Treatment decisions with greater...

Read more

Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System

June 29, 2022 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / June 29, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to be reviewing the financing for taking the steps on moving forward with its development process of. the Nanoemulsuion Drug Delivery System.Many anticancer drugs have been discovered and developed in the past few decades. Recently, drugs that were originally indicated for non-cancer diseases are also being...

Read more

BioInvent and Transgene Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA(R)

June 28, 2022 2:20 AM

LUND, SWEDEN / ACCESSWIRE / June 28, 2022 / BioInvent International (STO:BINV)Lund, Sweden - June 28, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the...

Read more

Transgene and BioInvent Announce Positive Progress for BT-001

June 27, 2022 2:20 AM

LUND, SE / ACCESSWIRE / June 27, 2022 / BioInvent International (STO:BINV)The oncolytic virus BT-001 replicates in the tumor for several days and expresses the anti-CTLA-4 monoclonal antibody.Lund, Sweden and Strasbourg, France - June 27, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer...

Read more

Hemogenyx Pharmaceuticals PLC Announces Investor Webinar

June 27, 2022 2:00 AM

LONDON, UK / ACCESSWIRE / June 27, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that Dr Vladislav Sandler, Chief Executive Officer & Co-Founder of Hemogenyx Pharmaceuticals, will host a live investor webinar on 6 July 2022 at 16:00 BST at which he will present an overview of the Company's activities and immediate future directions of its work, and will answer questions about the Company's current activities. If you...

Read more

SEC Cancels Regulatory Penalty and Interest Concerning Legacy Civil Enforcement Action

June 22, 2022 12:00 AM

SAN DIEGO, CA / ACCESSWIRE / June 22, 2022 / Plandai Biotechnology Inc. (OTC PINK:PLPL) (the "Company") today announced that the U.S. Securities and Exchange Commission canceled civil penalties and interest totaling approximately $200,000 related to the Commission's 2018 action against the Company and its former Chairman of the Board and CEO, Mr. Roger Duffield.Tad Mailander, the Company's CEO and director commented, "I am pleased to report that...

Read more